1137results about "Bacteriophages" patented technology

The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

The invention relates to methods and compositions for treating or preventing an infection by E coli cells in human or animal subjects. The method comprises administering to the subject a plurality of transduction particles that encode a nuclease for targeting the genomes of B2 phylogroup E coli cells.

The invention provides a virulent bacteriophage and application thereof, the virulent bacteriophage is named as vBVpaPChan1 and has been preserved in China Center for Type Culture Collection on December 10, 2024, the preservation address is Wuhan University, Wuhan, Hubei, China, and the preservation number is CCTCC M 20242772. The bacteriophage is safe, environmentally friendly and free of toxic and side effects, and compared with known bacteriophages, the bacteriophage is short in incubation period, large in outbreak amount and capable of effectively killing diseases caused by vibrio parahaemolyticus chan02.

The invention discloses a virulent bacteriophage vBValSR36H with a host being vibrio alginolyticus and application of the virulent bacteriophage vBValSR36H, and relates to the technical field of microbial control. The invention provides a bacteriophage capable of efficiently cracking Vibrio alginolyticus ATCC 17749T, the bacteriophage is named as vBValSR36H, the preservation number is 66248-B1, and the preservation address is Institute of Microbiology, Academy of Sciences in Guangdong Province. The vibrio alginolyticus bacteriophage vBValSR36H provided by the invention has good environmental stability and certain bactericidal activity, and has a relatively wide environmental adaptation range and relatively long survival time. The bacteriophage vBValSR36H provided by the invention can specifically and effectively kill, prevent and control related vibrio diseases, meanwhile, virulence factor genes and drug-resistant genes are not detected in the bacteriophage, and the bacteriophage vBValSR36H has the advantages of no toxic or side effect, high safety, environmental friendliness and wide application prospect. Therefore, the vibrio alginolyticus bacteriophage vBValSR36H can be completely applied to killing and / or preventing vibrio alginolyticus for non-disease diagnosis and treatment purposes.

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

The present disclosure provides virus-like particles (VLPs) for delivering prime editors, and systems comprising such prime editor (PE) VLPs. The present disclosure also provides polynucleotides encoding the PE-VLPs described herein, which may be useful for producing said PE-VLPs. Also provided herein are methods for editing the genome of a target cell by introducing the presently described PE-VLPs into the target cell. The present disclosure also provides fusion proteins that make up a component of the PE-VLPs described herein, as well as polynucleotides, vectors, cells, and kits.

The technology described herein relates to methods and compositions for targeting E coli cells, such as for treating or preventing an infection by E coli cells in human or animal subjects. The method, in an embodiment, comprises administering to the subject a particle cocktail comprising a plurality of different transduction particles to E coli cells. The method, in an embodiment, comprises administering to the subject a plurality of transduction particles that encode a nuclease for targeting the genomes of B2 phylogroup E coli cells.

The invention discloses stenotrophomonas maltophilia bacteriophage, a composition and application thereof. Relates to the technical field of biology, the stenotrophomonas maltophilia bacteriophage comprises a bacteriophage vBSma-SZP9, the taxonomic name of the bacteriophage vBSma-SZP9 is Snotrophomonas phage, the Latin literature name of the bacteriophage vBSma-SZP9 is Snotrophomonas phage, the bacteriophage vBSma-SZP9 is preserved in the Guangdong Microbiological Culture Collection Center, the preservation address is the fifth floor of the building 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation number is GDMCC No: 64509-B1, and the preservation date is May 16, 2024. The bacteriophage disclosed by the invention is wide in host spectrum, strong in infection ability and wide in temperature and acid-base tolerance range.

Strategies, systems, methods, reagents, and kits for phage-assisted continuous evolution are provided herein. These include strategies, systems, methods, reagents, and kits allowing for stringency modulation to evolve weakly active or inactive biomolecule variants, negative selection of undesired properties, and / or positive selection of desired properties.

The invention discloses a lytic bacteriophage vBVpaSR40Z and application of the lytic bacteriophage vBVpaSR40Z to prevention and control of vibrio parahaemolyticus in an aquaculture environment. The preservation number of the vibrio parahaemolyticus phage vBVpaSR40Z is as follows: GDMCC No: 67440-B1, and the vibrio parahaemolyticus phage vBVpaSR40Z is The R40Z can be used for cracking multiple strains of vibrio parahaemolyticus and vibrio alginolyticus, has the capability of adapting to an aquaculture environment, and keeps relatively high activity within the range of 4-25 DEG C and pH of 4-10; no virulence gene or drug-resistant gene is detected through genome analysis, and phylogenetic and whole genome comparison shows that the similarity between R40Z and a related phage is lower than a species level threshold value, so that R40Z is a new phage species; the R40Z can obviously inhibit the growth of a host under various infection complex numbers. The R40Z has the advantages of strong splitting capacity, good environmental stability, high genome safety, unique evolutionary characteristics and the like, and is an aquatic vibriosis biological prevention and control bacteriophage with application potential.

The invention discloses an Escherichia coli bacteriophage PEC-36 with cross-species host characteristics and application of the Escherichia coli bacteriophage PEC-36, and belongs to the technical field of biology. The Escherichia coli bacteriophage PEC-36 is separated from sewage of a pig factory, can simultaneously split O8: H7, O21: H34, O23: H16, O25: H4, O81: H27 and H25 serotype strains of Escherichia coli and fowl typhoid, London, swine cholera and other serotype strains of salmonella, and has a cross-species splitting characteristic. Experiments prove that the bacteriophage has the advantages of high titer, high stability, high safety and the like, and can remarkably inhibit the growth of escherichia coli and salmonella, so that a technical support is provided for research and development of bacteriophage preparations for treating infection related to escherichia coli and salmonella; the invention provides a safe and efficient antibiotic alternative scheme for treating human and animal Escherichia coli and salmonella related infection, and has a good application prospect.

The invention discloses a lytic bacteriophage for preventing and controlling vibrio in an aquaculture environment. The bacteriophage vBValMR42H belongs to a muscle tail bacteriophage and is insensitive to chloroform, the capsid of the bacteriophage vBValMR42H is free of lipid substances, and the preservation number is GDMCC No: 67434-B1. The bacteriophage has the characteristics of high adsorption speed, short incubation period and high cracking amount, keeps high activity in a wide range of temperature (4-55 DEG C) and pH (2-11), and has strong environmental adaptability. Genome analysis shows that the bacteriophage does not contain virulence factors, antibiotic resistance genes and lyogen related genes, and is high in biological safety. Physical development analysis shows that the method can be divided into a new genus. The bacteriophage R42H has the advantages of high splitting efficiency, good environmental stability, strong specificity, gene safety and the like, and can be used as an ideal biological prevention and control agent for preventing and controlling vibrio alginolyticus diseases in aquaculture.

The invention relates to the technical field of microorganisms, in particular to a bacteriophage capable of splitting a high-risk escherichia coli clone strain and targeting multiple serotypes and application of the bacteriophage. The invention discloses a bacteriophage capable of splitting a high-risk escherichia coli clone strain and targeting multiple serotypes, the bacteriophage is named as Escherichia phage vBEcoM32M3Y, the bacteriophage is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.45969. The invention further discloses a preparation method of the bacteriophage. The bacteriophage disclosed by the invention is low in MOI, good in stability, good in cracking activity, free of drug-resistant and virulence genes in a genome sequence, and relatively good in clinical application value.

Provided are circular RNAs (circRNAs) encoding an antigenic polypeptide of a SARS-CoV-2 variant. Provided are circRNA vaccines against a SARS-CoV-2 variant, such as a Delta or Omicron variant. The circRNA vaccine comprises a circRNA comprising a nucleic acid sequence encoding an antigenic polypeptide comprising a Spike(S) protein or a fragment thereof of a SRAS-CoV-2 variant. Also provided are methods of treating or preventing a SARS-CoV-2 infection using the circRNAs or compositions thereof.

The invention belongs to the technical field of microorganisms, and relates to a riemerella anatipestifer phage and application thereof. The riemerella anatipestifer bacteriophage provided by the invention is RA-XHX1, is preserved in the China Center for Type Culture Collection (CCTCC), has the preservation number of CCTCC NO: M 20241268, and is classified and named as the riemerella anatipestifer bacteriophage. The bacteriophage is double-stranded DNA (Deoxyribose Nucleic Acid) and myuroviridae, can form transparent plaques on a solid culture medium, has no halo ring around and is clear and regular in edge; the bacteriophage has a relatively good killing effect on riemerella anatipestifer in a space environment, particularly high-pathogenicity riemerella anatipestifer, and can realize a broad-spectrum antibacterial effect when being applied to preparation of medicines for preventing and treating riemerella anatipestifer infection.

A bacteriophage for specifically lysing high-virulence capsular Klebsiella pneumoniae, pertaining to the field of microorganisms. The deposit number of the Klebsiella pneumoniae bacteriophage vB_kpnP_D39 is CCTCC NO: M 2024690. In the bacteriophage liquid formulation prepared on the basis of the bacteriophage, the working titer of the bacteriophage is greater than 1 × 109 PFU / mL. The bacteriophage has high specificity and can kill all high-virulence multidrug-resistant Klebsiella pneumoniae of K1, K2, and K57 capsular serotypes, with an adsorption efficiency of 99.60%. The bacteriophage exhibits a biofilm clearance rate of 47.4%-63.2% and a capsule clearance rate of 42.1%-60.6% against the high-virulence Klebsiella pneumoniae. The bacteriophage is expected to become a safe, non-toxic agent for the prevention, control, and treatment of high-virulence multidrug-resistant Klebsiella pneumoniae infections, or an antibiotic adjuvant.

The invention relates to the technical field of bacteriophages, and provides a bacteriophage for fish nocardia and application of the bacteriophage, the bacteriophage is used for splitting fish nocardia, and the fish nocardia comes from a water body of a fish culture pond; the bacteriophage is preserved in China General Microbiological Culture Collection Center (CGMCC) on June 17, 2025, and the preservation number is CGMCC No.46495; the bacteriophage belongs to a tail bacteriophage, and the tail length is 165 + / -2nm. According to the technical scheme, the problem that at present, no bacteriophage for effectively treating and preventing fish nocardia exists is solved.

The invention discloses a high-temperature-resistant klebsiella pneumoniae phage, a composition of the high-temperature-resistant klebsiella pneumoniae phage and a kit, the high-temperature-resistant klebsiella pneumoniae phage is klebsiella pneumoniae phage P6AKPJS20, the preservation number of the high-temperature-resistant klebsiella pneumoniae phage is CCTCC (China Center For Type Culture Collection) NO: M20242965, and the high-temperature-resistant klebsiella pneumoniae phage has a nucleotide sequence as shown in SEQ ID No.1-6. The bacteriophage has broad-spectrum bactericidal ability, wide acid-base tolerance range and certain tolerance to chloroform and diethyl ether, and can still maintain high activity while splitting target bacteria; meanwhile, the bacteriophage has good tolerance to high temperature and can adapt to various application conditions in production.

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

The invention provides systems, methods, reagents, apparatuses, vectors, and host cells for the continuous evolution of nucleic acids. For example, a lagoon is provided in which a population of viral vectors comprising a gene of interest replicates in a stream of host cells, wherein the viral vectors lack a gene encoding a protein required for the generation of infectious viral particles, and wherein that gene is expressed in the host cells under the control of a conditional promoter, the activity of which depends on a function of the gene of interest to be evolved. Some aspects of this invention provide evolved products obtained from continuous evolution procedures described herein. Kits containing materials for continuous evolution are also provided.

The invention discloses a klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 and application thereof, and relates to the technical field of biology. The klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 65268-B1. The bacteriophage keeps stable titer in a wide pH range (4-10) and a temperature interval (4-50 DEG C), and the highest titer can reach more than 109 pfu / mL. The bacteriophage can efficiently split klebsiella pneumoniae. The invention provides powerful technical support for developing novel antibacterial drugs and treatment schemes for klebsiella pneumoniae, and shows wide application prospect and potential clinical value.

The invention relates to the field of aquaculture, and particularly discloses a high-splitting-property aeromonas caviridis bacteriophage and application of the high-splitting-property aeromonas caviridis bacteriophage. The invention relates to a high-cracking aeromonas caviridis phage, which has a preservation name of RKP-AE24001, is preserved in No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing on June 14, 2024, and has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.45944. According to the invention, a strain of aeromonas cainea is separated, the strain of aeromonas cainea bacteriophage is separated by taking the strain as a host, and the aeromonas cainea bacteriophage has a strong splitting effect on the aeromonas cainea separated in a culture environment.

The present invention concerns engineered phagemids and methods for antibacterial peptide delivery against bacterial pathogens, in particular Clostridioides difficile.

Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and / or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.

The present invention relates to the technical field of phages. Provided are a KL2-type Acinetobacter baumannii phage and a screening method therefor, a phage composition and the use, and a drug. The KL2-type Acinetobacter baumannii phage is named AB_SZL2, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241522; or the KL2-type Acinetobacter baumannii phage is named AB_SZL3, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241523. The KL2-type Acinetobacter baumannii phage can accurately target KL2-type Acinetobacter baumannii, and has an efficient bactericidal effect, thereby reducing the harm of KL2-type Acinetobacter baumannii and effectively addressing the problem of the antibiotic resistance of KL2-type Acinetobacter baumannii.

The invention relates to a clostridium perfringens phage and application thereof. The bacteriophage is a clostridium perfringens bacteriophage P2ACQJS03 (wherein the clostridium perfringens bacteriophage P2ACQJS03), and the preservation number of the clostridium perfringens bacteriophage P2ACQJS03 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 20242430. The bacteriophage provided by the invention is a virulent bacteriophage separated from the nature, tests prove that the bacteriophage has no toxic effect on normal microbial flora, and the DNA of the bacteriophage cannot encode virulence genes, so that the bacteriophage is high in stability; the bacteriophage disclosed by the invention is wide in host range, and large-scale industrial production can be realized. The bacteriophage provides an excellent strain resource for developing a novel antibacterial preparation, and has a good application and development prospect.

The invention discloses application of a method for enhancing the treatment effect of salmonella bacteriophage, and relates to the technical field of microorganisms. According to the method, bacteriophage is added into salmonella for in-vitro culture, after continuous subculture, the salmonella is dropwise added to an SS plate containing the bacteriophage, and resistant bacteria of the bacteriophage are screened. The split bacteriophage is screened aiming at the resistant bacteria of the bacteriophage, and the split bacteriophage and the initial bacteriophage form a bacteriophage cocktail formula, so that the salmonellosis can be well prevented and treated, and the generation of the resistant bacteria is delayed. The method has the beneficial effects that compared with the existing method for screening the bacteriophage-resistant bacteria through a double-layer plate method, the method is more convenient, the operation is simple, and the screening efficiency of the bacteriophage-resistant bacteria is greatly improved. The bacteriophage cocktail contains the bacteriophage for cracking the resistant bacteria, so that the treatment effect of the bacteriophage is improved, and the practical application scene is quite high.

The invention discloses a composite antibacterial preparation containing antibacterial peptide and traditional Chinese medicines as well as a preparation method and application of the composite antibacterial preparation, and belongs to the technical field of biological medicines. The antibacterial peptide provided by the invention is a transmembrane protein derived from bacteriophage, and the core function of the antibacterial peptide is that bacterial cell lysis is promoted by destroying a connection structure of a peptidoglycan layer and lipoprotein of a bacterial cell wall, so that an antibacterial effect is achieved. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 3, the antibacterial peptide is combined with traditional Chinese medicines to form a composite antibacterial preparation, and experiments prove that the composite antibacterial preparation has a relatively good antibacterial effect on gram-positive bacteria and gram-negative bacteria and can be applied to the medical field, such as surgical instrument disinfection and drug-resistant bacterial infection treatment; the field of daily chemicals, such as antibacterial hand sanitizers and wound dressings; in the field of agriculture, for example, animal feed additives for preventing and treating intestinal infection have a good market application prospect.